Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OCUCLEAR vs NAPHAZOLINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Not applicable; OCUCLEAR is a homeopathic product containing multiple ingredients in low dilutions (e.g., Euphrasia officinalis, Calendula officinalis, etc.). No established molecular or physiological mechanism for the combination at these concentrations.
Agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of conjunctival blood vessels and reducing nasal mucosal congestion.
Relief of minor eye irritations due to dryness, allergies, or overuse
Ocular: relief of redness, itching, and irritation due to minor eye irritations or allergic conjunctivitis. Nasal: temporary relief of nasal congestion due to colds, allergies, or sinusitis.
1 drop in each eye twice daily (morning and evening) as ophthalmic solution.
1-2 drops of 0.1% solution in each eye every 3-4 hours as needed; intranasal: 0.05% solution, 1-2 sprays per nostril every 6-8 hours.
Terminal elimination half-life is approximately 20-24 hours; allows once-daily dosing in most patients, but may be prolonged in renal impairment.
Approximately 2-3 hours after systemic absorption; clinical effect is limited by local vasoconstriction rather than plasma half-life.
Not applicable; active ingredients are present in extremely low concentrations (typically 6X to 30X potency) and are not expected to undergo significant systemic metabolism.
Not extensively studied; likely hepatic metabolism via unknown enzymes.
Renal excretion of unchanged drug and metabolites accounts for >90% of elimination; biliary/fecal excretion is minor (<10%).
Primarily renal excretion of unchanged drug and metabolites; exact % not established in humans due to limited systemic absorption after topical use. In animal studies, ~30-40% excreted unchanged in urine.
Plasma protein binding is approximately 99%, primarily to albumin.
Not well characterized; expected to be low (<20%) based on structural analogs.
Volume of distribution is 0.1-0.3 L/kg, indicating minimal extravascular distribution and high intravascular retention.
Not established in humans; based on animal data, approximately 0.5-1.0 L/kg, suggesting distribution into total body water.
Oral bioavailability is 90-100%, consistent with nearly complete absorption.
Ophthalmic and intranasal: low systemic bioavailability due to local vasoconstriction limiting absorption; exact % not determined, estimated <1%.
No dosage adjustment required for renal impairment; however, use caution in severe renal disease (Cr Cl <30 m L/min) due to potential systemic absorption.
No dose adjustment required; primarily locally acting with minimal systemic absorption.
No formal studies in hepatic impairment; use caution in Child-Pugh class C (severe) due to possible increased systemic exposure.
No dose adjustment required; use caution in severe hepatic impairment due to potential for systemic effects.
Safety and efficacy not established; use not recommended in pediatric patients under 18 years.
Children ≥6 years: 1-2 drops of 0.1% ophthalmic solution every 6-8 hours; nasal spray 0.05% for children ≥6 years, 1 spray per nostril every 8-10 hours. Contraindicated in infants and children <6 years due to risk of CNS depression.
No specific dose adjustment; monitor for increased intraocular pressure or systemic effects due to potential age-related changes in clearance.
Elderly patients may be more sensitive to adverse effects (e.g., rebound congestion, hypertension); use lowest effective dose and shortest duration. Avoid in patients with cardiovascular disease or glaucoma.
None
None
Do not use if solution changes color or becomes cloudy. Do not touch dropper tip to any surface to avoid contamination. Contact lens wearers should remove lenses before instillation and wait 10 minutes before reinserting. If symptoms persist or worsen, consult a physician.
Prolonged use may cause rebound congestion (rhinitis medicamentosa). Use with caution in patients with cardiovascular disease (hypertension, arrhythmias), hyperthyroidism, diabetes, or prostatic hyperplasia. Avoid use in patients with narrow-angle glaucoma. Do not exceed recommended dosage or duration.
Known hypersensitivity to any component. Not for use in patients with acute eye infection, glaucoma, or other serious eye conditions.
Hypersensitivity to naphazoline or any component. Narrow-angle glaucoma (ophthalmic use). Use with MAO inhibitors or within 14 days of stopping therapy (risk of hypertensive crisis).
No specific food interactions known for ophthalmic ketorolac. However, systemic NSAIDs can interact with alcohol (increased GI bleeding risk), but this is negligible with ocular use.
No significant food interactions; avoid excessive caffeine or other stimulants as they may potentiate sympathomimetic effects.
No adequate studies in pregnant women. Animal studies not available. Risk cannot be ruled out. Use only if potential benefit justifies risk.
Naphazoline hydrochloride is an alpha-adrenergic agonist used as a topical decongestant. Systemic absorption is minimal with topical ocular or nasal use; however, theoretical risks include vasoconstriction and reduced uterine blood flow. No adequate and well-controlled studies in pregnant women. Animal studies have not been reported. First trimester: No known teratogenic effects. Second and third trimesters: Potential risk of reduced uteroplacental perfusion when used systemically; topical use at recommended doses unlikely to cause significant effects. Overall, classified as FDA Pregnancy Category C. Caution is advised.
Unknown if excreted in human milk. Caution advised. M/P ratio not available.
Excretion in human milk is unknown. Due to low systemic absorption after topical application, amounts ingested by an infant are expected to be minimal. No known adverse effects in nursing infants. M/P ratio not reported. Consider benefit of treatment versus potential risk to infant. Use caution and avoid prolonged or excessive dosing.
No dose adjustment recommendations due to lack of data.
No dose adjustments required for topical ocular or nasal use due to minimal systemic absorption. Pharmacokinetic changes in pregnancy are not significant for topical administration. Use at standard recommended doses and avoid prolonged or excessive application.
Ocuclear (ketorolac tromethamine ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) used for ocular inflammation. Use with caution in patients with bleeding disorders or those on anticoagulants due to increased risk of ocular bleeding. Monitor for corneal epithelial effects with prolonged use. Contraindicated in patients with aspirin allergy or NSAID hypersensitivity.
Naphazoline is a direct-acting sympathomimetic with rapid onset; use limited to 3-5 days to avoid rebound congestion and rhinitis medicamentosa. Contraindicated in narrow-angle glaucoma due to potential mydriasis. Caution in cardiovascular disease, hypertension, and hyperthyroidism; may elevate BP and cause palpitations. Not for use in infants or children under 6 years due to risk of CNS depression.
Remove contact lenses before instillation and wait at least 10 minutes before reinserting.,Do not touch the dropper tip to any surface to avoid contamination.,Wash hands before and after use.,Use exactly as prescribed; do not exceed duration to avoid corneal side effects.,May cause transient stinging or blurred vision upon instillation.,Report any eye pain, vision changes, or signs of infection (redness, discharge) promptly.
Do not use for more than 3-5 consecutive days to avoid worsening congestion and dependence.,Avoid contact with eyes; if eye contact occurs, flush with water for 15 minutes.,Do not share the bottle with others to prevent infection spread.,Store at room temperature, away from light and moisture.,Consult a doctor before use if you have heart disease, high blood pressure, or an enlarged prostate.
No interactions on record
"Naphazoline, an alpha-1 adrenergic receptor agonist, induces vasoconstriction and elevates blood pressure. Co-administration with ergometrine, an ergot alkaloid that also causes potent vasoconstriction via serotonin and alpha-adrenergic receptor activation, results in additive or synergistic hypertensive effects. This combination significantly increases the risk of severe hypertension, hypertensive crisis, and potential end-organ damage such as stroke or myocardial ischemia."
"Naphazoline, an alpha-adrenergic agonist, can cause systemic vasoconstriction and reflex bradycardia. When combined with nadolol, a non-selective beta-blocker, the bradycardic effects may be additive, leading to an increased risk of atrioventricular (AV) block. This interaction can result in profound bradycardia, hypotension, and potential syncope, particularly in patients with pre-existing cardiac conduction abnormalities."
"Naphazoline, an alpha-adrenergic agonist with vasoconstrictive properties, can increase systemic blood pressure through peripheral vasoconstriction, which may counteract the antihypertensive effects of cyclobenzaprine, a centrally acting muscle relaxant that can lower blood pressure due to its sedative and alpha-blocking activities. This pharmacodynamic opposition may reduce the efficacy of cyclobenzaprine in managing hypertension or lead to inadequate blood pressure control. Clinically, patients may experience elevated blood pressure readings or require dose adjustments of antihypertensive therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OCUCLEAR vs NAPHAZOLINE HYDROCHLORIDE, answered by our medical review team.
OCUCLEAR is a Ophthalmic decongestant that works by Not applicable; OCUCLEAR is a homeopathic product containing multiple ingredients in low dilutions (e.g., Euphrasia officinalis, Calendula officinalis, etc.). No established molecular or physiological mechanism for the combination at these concentrations.. NAPHAZOLINE HYDROCHLORIDE is a Ophthalmic Decongestant that works by Agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of conjunctival blood vessels and reducing nasal mucosal congestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OCUCLEAR and NAPHAZOLINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OCUCLEAR is: 1 drop in each eye twice daily (morning and evening) as ophthalmic solution.. The standard adult dose of NAPHAZOLINE HYDROCHLORIDE is: 1-2 drops of 0.1% solution in each eye every 3-4 hours as needed; intranasal: 0.05% solution, 1-2 sprays per nostril every 6-8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OCUCLEAR and NAPHAZOLINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OCUCLEAR is classified as Category C. No adequate studies in pregnant women. Animal studies not available. Risk cannot be ruled out. Use only if potential benefit justifies risk.. NAPHAZOLINE HYDROCHLORIDE is classified as Category C. Naphazoline hydrochloride is an alpha-adrenergic agonist used as a topical decongestant. Systemic absorption is minimal with topical ocular or nasal use; however, theoretical risks. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.